- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07717970
Metabolomics-Driven Insights Into Ultra-Processed Foods
Metabolomics-Driven Insights Into Ultra-Processed Foods: Identifying High-Risk UPF Subtypes for T2D Prevention
The goal of this dietary intervention study in generally healthy adults is to develop new ways to use blood samples to measure the common types of highly processed foods and beverages that people eat on a regular basis. The main aims to answer are:
What small molecules are elevated in blood after eating different types of highly processed foods and beverages consistently for 1 week?
Researchers will compare 3 different test diets with 1 control diet that does not have any highly processed foods in the same individuals to see which circulating blood markers change.
Participants will:
- Complete 3 diet phases, each 2 weeks long
- Receive a meal plan and study foods and beverages to follow for each 2-week phase
- Come to the clinic every week for blood draws, urine samples, and stool collection kits
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Deirdre K Tobias, ScD
- Numéro de téléphone: 617-278-0844
- E-mail: dtobias@bwh.harvard.edu
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Brigham and Women's Hopital Center for Clinical Investigation
-
Contact:
- Yemi Talabi-Oates, MBA
- Numéro de téléphone: 617-732-8750
- E-mail: cci@bwh.harvard.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults, ages 20 to 65 years.
- BMI 18.5 to 39.9 kg/m2.
- No known food allergies, intolerances, or sensitivities (e.g., gluten, dairy, monosodium-glutamate).
- Not following a restrictive diet for health, religious, or other reasons (e.g., vegetarian, vegan).
- Willingness to participate and give informed consent.
- Willingness to consume dietary intervention foods and beverages.
Exclusion Criteria:
- BMI <18.5 or >39.9 kg/m2.
- Pregnant, lactating, or planning on becoming pregnant in the next 6 months.
- History of bariatric surgery.
- Currently taking medications impacting appetite or body weight.
- History of major chronic diseases, including cardiovascular disease, type 1 or 2 diabetes, major gastrointestinal conditions, uncontrolled hypertension (seated blood pressure systolic >140 mmHg or diastolic >90 mmHg), history of invasive cancer, current use of immunosuppressants, and other major chronic diseases and conditions affecting participation, adherence, or study endpoints.
- Unwilling or unable to comply with all in person scheduled visits, dietary protocols, study protocol, and other study procedures.
- Food allergies or aversions to the foods provided in the dietary interventions.
- Non-English speaking.
- Other members of the same household are already participating in the research study.
- Planning on moving out of the Boston area in the next 6 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Sequence 1
Participants receive Diet A, followed by Diet B, followed by Diet C.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Expérimental: Sequence 2
Participants receive Diet A, followed by Diet C, followed by Diet B.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Expérimental: Sequence 3
Participants receive Diet B, followed by Diet A, followed by Diet C.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Expérimental: Sequence 4
Participants receive Diet B, followed by Diet C, followed by Diet A.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Expérimental: Sequence 5
Participants receive Diet C, followed by Diet A, followed by Diet B.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Expérimental: Sequence 6
Participants receive Diet C, followed by Diet B, followed by Diet A.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Within-person metabolomic response during each UPF test diet, compared to the paired non-UPF control diet.
Délai: Day 0, Day 7, and Day 14 of each dietary intervention period
|
The primary outcome for this study is within-person metabolomic response during each UPF test diet, compared to the paired non-UPF control diet.
Metabolomic responses will be quantified from metabolite concentrations (e.g., relative abundance) measured in fasting plasma samples collected at day 0, day 7, and day 14 in each diet phase.
|
Day 0, Day 7, and Day 14 of each dietary intervention period
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Deirdre K Tobias, ScD, Brigham and Women's Hospital
- Chercheur principal: Shilpa Bhupathiraju, PhD, Brigham and Women's Hospital
- Chercheur principal: Frank B Hu, MD PhD, Harvard School of Public Health (HSPH)
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Techniques d'investigation
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Techniques cytologiques
- Techniques histologiques
- Techniques génétiques
- Techniques de préparation histocytologique
- Hybridation in situ
- Coloration et étiquetage
- Analyse cytogénétique
- Hybridation d'acide nucléique
- Hybridation in situ, fluorescence
Autres numéros d'identification d'étude
- 2026P001870
- 1R01DK145733-01A1 (Autre subvention/numéro de financement: NIH (Pending))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .